US Male Breast Cancer Market

ID: MRFR/Pharma/17391-HCR

100 Pages

Garvit Vyas

October 2025

US Male Breast Cancer Market Research Report By Type (Infiltrating Ductal Carcinoma, Inflammatory Breast Cancer, Paget Disease, Ductal Carcinoma), By Diagnosis (Mammography, Biopsy, Pet Scan, Others) and By Treatment (Local, Systemic) - Forecast to 2035

US Male Breast Cancer Market Infographic

Summary Table of Contents Segmentation Download PDF

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Certified Researchers

Customize Report

US Male Breast Cancer Market Summary

As per MRFR analysis, the US male breast cancer market size was estimated at 380.94 USD Million in 2024. The US male breast-cancer market is projected to grow from 414.19 USD Million in 2025 to 956.52 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.73% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The US male breast-cancer market is experiencing notable growth driven by increased awareness and innovative treatment options.

Rising awareness and advocacy efforts are significantly enhancing early detection and treatment rates among males.
Innovative treatment approaches, including targeted therapies, are becoming more prevalent in the male breast-cancer segment.
The integration of genetic testing is facilitating personalized treatment plans, particularly in the largest segment of diagnosed cases.
Increasing incidence rates and advancements in research and development are key drivers propelling market growth.

US Male Breast Cancer Market

CAGR

8.73%

Market Size & Forecast

2024 Market Size	380.94 (USD Million)
2035 Market Size	956.52 (USD Million)

Major Players

Roche (CH), Novartis (CH), Pfizer (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Merck & Co. (US), Eli Lilly and Company (US), Johnson & Johnson (US)

US Male Breast Cancer Market Trends

the male breast cancer market is experiencing significant changes, driven by increasing awareness and advocacy for male breast cancer. Historically, this condition has been overshadowed by its female counterpart, leading to a lack of research and funding. However, recent initiatives aimed at educating the public and healthcare professionals about the risks and symptoms associated with male breast cancer are beginning to change this narrative. As a result, there is a growing demand for diagnostic tools and treatment options tailored specifically for men. This shift in focus is likely to enhance early detection rates and improve patient outcomes. Moreover, advancements in treatment modalities, including targeted therapies and personalized medicine, are emerging as pivotal factors in the male breast-cancer market. These innovations not only promise to enhance the efficacy of treatments but also aim to minimize side effects, thereby improving the quality of life for patients. The integration of genetic testing and biomarker identification into clinical practice is expected to further refine treatment strategies, allowing for more precise interventions. As the landscape continues to evolve, stakeholders in the male breast-cancer market must remain vigilant and responsive to the changing needs of patients and healthcare providers alike.

Rising Awareness and Advocacy

There is a marked increase in awareness campaigns focused on male breast cancer, which is fostering greater public understanding. Advocacy groups are actively working to educate both men and healthcare professionals about the risks and symptoms, potentially leading to earlier diagnoses.

Innovative Treatment Approaches

The male breast-cancer market is witnessing the introduction of innovative treatment options, including targeted therapies. These advancements aim to improve treatment efficacy while reducing adverse effects, thereby enhancing patient quality of life.

Integration of Genetic Testing

The incorporation of genetic testing into treatment protocols is becoming more prevalent. This trend allows for personalized treatment plans based on individual genetic profiles, which may lead to more effective management of male breast cancer.

US Male Breast Cancer Market Drivers

Increasing Incidence Rates

The male breast-cancer market is experiencing a notable increase in incidence rates, which appears to be a significant driver for the industry. Recent data indicates that approximately 1.3% of all breast cancer cases in the US are diagnosed in men, with an estimated 2,650 new cases expected in 2025. This rising trend in diagnoses may lead to heightened demand for treatment options and support services, thereby expanding the market. Furthermore, as awareness grows regarding male breast cancer, more men are likely to seek medical advice, contributing to earlier detection and treatment. This shift in patient demographics and increased visibility of the disease could potentially reshape the landscape of the male breast-cancer market, prompting healthcare providers to adapt their strategies to meet the evolving needs of this patient population.

Impact of Public Health Campaigns

Public health campaigns aimed at increasing awareness of male breast cancer are playing a pivotal role in shaping the male breast-cancer market. These initiatives, often spearheaded by health organizations and advocacy groups, seek to educate the public about the risks and symptoms associated with male breast cancer. As these campaigns gain momentum, they may lead to a greater understanding of the disease among men, prompting earlier detection and treatment. The potential for increased screening rates could significantly influence market dynamics, as more men seek medical attention. Furthermore, the visibility created by these campaigns may encourage pharmaceutical companies to invest in research and development for male-specific treatments, thereby driving innovation within the male breast-cancer market.

Growing Support Networks and Resources

The establishment of growing support networks and resources for male breast cancer patients is becoming a crucial driver in the male breast-cancer market. Organizations dedicated to raising awareness and providing support are increasingly emerging, offering resources tailored specifically for men. These networks not only facilitate access to information but also foster community among patients, which can be vital for emotional and psychological well-being. As these support systems gain traction, they may encourage more men to seek diagnosis and treatment, thereby increasing market demand. Additionally, the presence of these resources can enhance the overall patient experience, potentially leading to improved treatment adherence and outcomes, which are essential for the growth of the male breast-cancer market.

Advancements in Research and Development

Ongoing advancements in research and development are poised to significantly impact the male breast-cancer market. The industry is witnessing a surge in funding for research initiatives aimed at understanding the unique biological mechanisms of male breast cancer. This focus on R&D is likely to lead to the discovery of novel therapeutic agents and treatment modalities tailored specifically for men. For instance, the National Cancer Institute has allocated substantial resources to studies exploring genetic predispositions and targeted therapies. As these innovations emerge, they may enhance treatment efficacy and improve patient outcomes, thereby driving growth in the male breast-cancer market. The potential for breakthrough therapies could also attract investment from pharmaceutical companies, further stimulating market expansion.

Insurance Coverage and Reimbursement Policies

Insurance coverage and reimbursement policies are critical factors influencing the male breast-cancer market. As awareness of male breast cancer increases, insurance providers are beginning to recognize the necessity of covering diagnostic and treatment services for male patients. Recent changes in policy have led to improved access to care, which may encourage more men to pursue necessary medical interventions. For instance, some insurance plans are now offering coverage for genetic testing and targeted therapies, which were previously limited. This shift in reimbursement practices could potentially lead to a broader acceptance of treatment options, thereby expanding the male breast-cancer market. As more men receive coverage for their healthcare needs, the overall market dynamics may evolve, reflecting a more inclusive approach to male breast cancer.

Market Segment Insights

By Type: Infiltrating Ductal Carcinoma (Largest) vs. Ductal Carcinoma in Situ (Fastest-Growing)

The market distribution of the segment values reveals that Infiltrating Ductal Carcinoma holds the largest share, highlighting its prominence in the US male breast-cancer market. Currently, Ductal Carcinoma in Situ is emerging as the fastest-growing segment, as increasing awareness and early detection contribute to its rising prevalence. Paget’s Disease of the Nipple and Inflammatory Breast Cancer remain smaller segments but play significant roles in comprehension and treatment responses among healthcare providers. Growth trends indicate a gradual shift towards targeted therapies and precision medicine, which are essential in treating Infiltrating Ductal Carcinoma. The increasing incidence of Ductal Carcinoma in Situ, influenced by advancements in medical imaging and screening practices, is expected to continue. Additionally, ongoing research and clinical trials focused on improving outcomes for Inflammatory Breast Cancer may also fuel market dynamics in the foreseeable future.

Infiltrating Ductal Carcinoma (Dominant) vs. Ductal Carcinoma in Situ (Emerging)

Infiltrating Ductal Carcinoma is characterized by its aggressive nature and is the most commonly diagnosed form among male breast cancer cases, thus holding the dominant position in treatment protocols and patient outcomes. This segment is recognized for its complexity, with multifaceted treatment options ranging from chemotherapy to targeted therapies. In contrast, Ductal Carcinoma in Situ represents an early form of ductal cancer, not yet invasive, making it a critical focus for early intervention strategies. Its emerging status is due to increasing screenings leading to earlier diagnoses and a growing body of research aimed at understanding its long-term implications within male patients. Together, these segments highlight the diversity and evolving landscape of the market.

By Diagnosis: Mammography (Largest) vs. Biopsy (Fastest-Growing)

The US male breast-cancer market features a diverse array of diagnostic methods. Mammography remains the largest segment, accounting for a significant share of overall diagnoses, while various biopsy techniques are gaining traction in clinical settings. Among the biopsy methods, Fine Needle Aspiration Biopsy, Core Biopsy, and Excisional Biopsy are crucial for accurate tissue sampling, each contributing to the overall distribution of diagnostic procedures within the market. Growth trends indicate a shift towards more advanced and minimally invasive diagnostic techniques, particularly in biopsy methods. Factors driving this growth include increasing awareness of male breast cancer, advancements in technology, and a rise in screening initiatives. As healthcare providers seek accurate and efficient diagnostic tools, the adoption of PET Scans, CT Scans, and MRIs is also on the rise, enhancing the overall diagnostic landscape.

Mammography (Dominant) vs. Biopsy (Emerging)

Mammography is recognized as the dominant diagnostic modality in the US male breast-cancer market, primarily due to its efficacy in early detection and widespread acceptance among clinical practitioners. This method utilizes low-energy X-rays to examine breast tissue, making it an essential tool for screening and preventive care. Conversely, biopsy methods, particularly Fine Needle Aspiration Biopsy and Core Biopsy, represent an emerging segment that is gaining momentum. These techniques offer minimally invasive solutions for tissue examination, improving patient comfort and diagnostic accuracy. As more healthcare facilities invest in cutting-edge biopsy technologies, the competitive landscape evolves, positioning these methods as vital alternatives in the diagnostic process.

By Treatment: Local Treatments (Largest) vs. Systemic Treatments (Fastest-Growing)

In the treatment segment, Local Treatments dominate the market with a significant share, contributing to the majority of the therapeutic options available for male breast cancer patients. This segment includes surgeries and localized therapies that have been traditional choices, allowing for targeted interventions with fewer systemic side effects. Meanwhile, Systemic Treatments are gaining traction, reflecting a shift in approach where male breast cancer is treated with medications that impact the whole body, including chemotherapy and hormonal therapies. The growth trends within the treatment segment highlight an increasing preference for Systemic Treatments, which are rapidly becoming essential in the care continuum for male breast cancer patients. Factors driving this growth include advancements in drug development, a better understanding of hormonal influences in male breast cancer, and expanding clinical indications for systemic therapies. As research continues to evolve, these treatments are expected to see accelerated adoption and integration into standard care practices, reflecting the dynamic nature of the therapeutic landscape.

Local Treatments: Dominant vs. Systemic Treatments: Emerging

Local Treatments, encompassing surgical interventions and localized therapies, play a dominant role in managing male breast cancer, reflecting the historical treatment paradigms. Surgeons and oncologists utilize these methods to directly target tumors, aiming for the best outcomes while minimizing systemic exposure. Conversely, Systemic Treatments represent an emerging approach characterized by the use of pharmaceuticals to treat cancer at a systemic level. This category is rapidly evolving, driven by innovations in treatment protocols and a deeper understanding of the disease. As these treatments become more widely accepted, they complement local therapies, creating a comprehensive treatment strategy designed to enhance patient outcomes and provide tailored care.

By Local Treatments: Surgery (Largest) vs. Radiation Therapy (Fastest-Growing)

In the segment of local treatments for male breast-cancer, surgery holds the largest market share, primarily due to its established role as a primary intervention. This procedure involves removing the tumor and is often considered the first line of defense against localized breast cancer. In contrast, radiation therapy is gaining traction rapidly, carving out a significant portion of the market as an adjunct treatment used post-surgery to eliminate residual cancer cells and reduce recurrence rates. Growth trends in the local treatments segment are primarily driven by advancements in surgical techniques and technology, which enhance recovery times and outcomes. Additionally, increased awareness and early detection contribute to the upward trajectory of both treatment methods. The integration of radiation therapy, particularly targeted therapy approaches, is expected to grow faster due to its effectiveness and lesser invasiveness compared to traditional surgical methods.

Surgery: Dominant vs. Radiation Therapy: Emerging

Surgery remains the dominant local treatment in the market, characterized by its comprehensive approach to tumor removal and established protocols, leading to favorable outcomes for patients. In contrast, radiation therapy represents an emerging trend, leveraging new technologies such as precision and intensity-modulated radiation to maximize treatment effectiveness while minimizing side effects. As oncologists continue to refine their approaches, both methods are expected to coexist, with surgery serving as a foundational treatment option and radiation therapy expanding its role in post-surgical care.

By Surgery: Mastectomy (Largest) vs. Breast-Conserving Surgery (Fastest-Growing)

In the US male breast-cancer market, Mastectomy holds a significant share, primarily due to its historical precedence as a primary surgical intervention for breast cancer. It is often favored in cases involving larger tumors or multiple affected areas, leading to its dominance. In contrast, Breast-Conserving Surgery is gaining traction as awareness increases about the benefits of less invasive procedures and effective treatment outcomes, reflecting changing patient preferences and clinical guidelines. Growth trends indicate a shift towards Breast-Conserving Surgery, driven by advancements in surgical techniques and technology. This segment is expected to grow rapidly as more patients opt for options that preserve breast integrity and aesthetics. Furthermore, Lymph Nodes Biopsy, while crucial for staging, occupies a smaller niche, primarily supporting the larger surgery segments while enjoying stable demand, yet not contributing significantly to overall growth compared to the other two.

Mastectomy (Dominant) vs. Breast-Conserving Surgery (Emerging)

Mastectomy remains the dominant surgical approach for male breast cancer, particularly favored for its comprehensive treatment potential in advanced cases. It provides extensive tissue removal, mitigating recurrence risks, which is critical in aggressive cancer types. On the other hand, Breast-Conserving Surgery is emerging as a preferred option for early-stage cancers, reflecting a trend towards preserving quality of life and minimizing physical changes post-surgery. This shift is supported by ongoing research and clinical trials affirming its efficacy. As patient advocacy grows around treatment options that retain body integrity, Breast-Conserving Surgery is positioned for considerable uptake, presenting an evolving landscape in surgical cancer treatments.

By Systemic Treatments: Chemotherapy (Largest) vs. Targeted Therapy (Fastest-Growing)

In the systemic treatments segment, chemotherapy holds the largest market share, being the most commonly utilized therapeutic option for male breast cancer. Hormone therapy follows as a significant player, while targeted therapy is rapidly gaining traction among healthcare providers and patients. This distribution reflects the established efficacy and familiarity of chemotherapy in treatment protocols, with hormone therapy maintaining its relevance due to its specific applications in hormone-sensitive cancers. The growth trends in the systemic treatments segment are primarily driven by increased awareness and early diagnosis of male breast cancer, leading to higher treatment adoption rates. The expanding research and development in targeted therapies play a crucial role in enhancing treatment outcomes, driving the need for innovative solutions. Moreover, the growing investment in healthcare infrastructure and technology is expected to further boost the overall growth of systemic treatments in the market.

Chemotherapy: Dominant vs. Targeted Therapy: Emerging

Chemotherapy is regarded as the dominant treatment modality in systemic therapies for male breast cancer, with its well-established protocols and widespread acceptance among medical professionals. Its efficacy in reducing tumor size and eliminating cancer cells has made it a cornerstone in treatment regimens. Conversely, targeted therapy is emerging as a powerful alternative, utilizing drugs that specifically target cancerous cells while minimizing damage to surrounding healthy tissues. This approach not only promises improved efficacy but also reduced side effects, which are critical in treatment adherence. As research progresses and more targeted options become available, this segment is attracting significant interest from both clinicians and patients, indicating a shift in therapeutic strategies within the US male breast-cancer market.

By Chemotherapy: Adjuvant Therapy (Largest) vs. Neoadjuvant Therapy (Fastest-Growing)

In the US male breast-cancer market, the distribution between Adjuvant and Neoadjuvant Therapy showcases Adjuvant Therapy as the largest segment due to its established role in enhancing treatment outcomes post-surgery. While Adjuvant Therapy has been the cornerstone of post-operative care for years, Neoadjuvant Therapy is gaining traction, particularly as an innovative approach for downstaging tumors and facilitating surgical intervention. Growth trends in the chemotherapy segment indicate a significant shift towards Neoadjuvant Therapy, which is emerging as the fastest-growing option. Factors driving this trend include advancements in personalized medicine and the increasing need for less invasive treatment modalities. As healthcare providers and patients seek effective yet less aggressive options, Neoadjuvant Therapy aligns well with these evolving demands, showing robust potential for growth in the upcoming years.

Adjuvant Therapy (Dominant) vs. Neoadjuvant Therapy (Emerging)

Adjuvant Therapy remains the dominant treatment in the chemotherapy segment, primarily aimed at eliminating residual cancer cells post-surgery. This approach is well-recognized for its efficacy in reducing recurrence rates and improving survival outcomes. In contrast, Neoadjuvant Therapy is emerging as a compelling alternative, particularly for patients with larger tumors. It allows for the administration of chemotherapy before surgery, potentially shrinking tumors and making them operable. Both therapies are being continuously evaluated in clinical settings, but the trend is leaning towards Neoadjuvant Therapy as it presents an opportunity to tailor treatment strategies to individual patient needs effectively.

By Hormone Therapy: Using Drugs (Largest) vs. Orchiectomy (Castration) (Fastest-Growing)

Within the hormone therapy segment, 'Using Drugs' holds the largest share, reflecting a significant preference among the population. This segment's robust presence is supported by various therapeutic agents being utilized to treat hormone-sensitive tumors effectively. On the other hand, 'Orchiectomy' is emerging as the fastest-growing option, driven by increasing awareness and the effectiveness of this surgical method in managing hormone levels. Patients are increasingly leaning towards this approach due to its potential for quick results and lower long-term medication dependence, making it appealing in clinical practice.

Using Drugs (Dominant) vs. Orchiectomy (Castration) (Emerging)

The 'Using Drugs' segment is characterized by a wide selection of hormonal agents that are prescribed based on patient-specific conditions. These drugs, including antiandrogens and aromatase inhibitors, offer targeted therapy resulting in improved patient outcomes. Conversely, the 'Orchiectomy' approach is gaining traction as a major surgical intervention. It effectively reduces testosterone levels, providing a swift resolution to hormone-related issues in male breast cancer. The growing acceptance of this method, coupled with advancements in surgical techniques, positions it as an emerging trend in the treatment landscape.

By Targeted Therapy: For HER2 Positive Breast Cancer (Largest) vs. For Hormone Receptor Positive Breast Cancer (Fastest-Growing)

In the US male breast-cancer market, the segment for HER2 Positive Breast Cancer currently holds the largest market share, reflecting a strong preference among clinicians and patients for targeted therapies that specifically address this genetic variant. This segment benefits from ongoing research and the successful incorporation of innovative therapies that enhance patient outcomes, thus leading to a higher adoption rate. On the other hand, the Hormone Receptor Positive Breast Cancer segment is rapidly growing, driven by an increasing awareness of hormonal influences on breast cancer progression and the development of effective targeted treatment options. This growth is supported by advancements in personalized medicine, which are improving therapeutic effectiveness and patient compliance, making it a focal point for market expansion in the coming years.

For HER2 Positive Breast Cancer (Dominant) vs. For Hormone Receptor Positive Breast Cancer (Emerging)

The HER2 Positive Breast Cancer segment is recognized as the dominant force in the targeted therapy landscape, largely due to the success of therapies like trastuzumab, which have transformed treatment protocols and improved survival rates. This segment is characterized by its robust pipeline of novel therapeutics aiming at enhancing treatment efficacy. Conversely, the Hormone Receptor Positive Breast Cancer segment is emerging with rapid developments in treatment strategies, including novel hormone therapies and immunotherapies that are tailored to individual patient profiles. This increasing focus on personalized treatment is enabling this segment to grow significantly as healthcare providers emphasize the importance of targeted approaches in managing breast cancer effectively.

Get more detailed insights about US Male Breast Cancer Market

Request Free Sample

Key Players and Competitive Insights

The male breast-cancer market is currently characterized by a competitive landscape that is both dynamic and evolving. Key growth drivers include increasing awareness of male breast cancer, advancements in treatment options, and a growing emphasis on personalized medicine. Major players such as Roche (CH), Pfizer (US), and AstraZeneca (GB) are strategically positioned to leverage these trends. Roche (CH) focuses on innovation through its robust pipeline of targeted therapies, while Pfizer (US) emphasizes partnerships to enhance its research capabilities. AstraZeneca (GB) is actively pursuing regional expansion, particularly in underserved markets, which collectively shapes a competitive environment that is increasingly collaborative yet fiercely competitive.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to emerge, yet the collective strength of major companies like Bristol-Myers Squibb (US) and Merck & Co. (US) ensures that competition remains robust and innovation-driven.

In October 2025, Roche (CH) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunotherapy for male breast cancer. This collaboration is significant as it not only enhances Roche's research capabilities but also positions the company to potentially lead in a niche yet critical area of oncology. The partnership underscores the importance of innovation and collaboration in addressing unmet medical needs in this market.

In September 2025, Pfizer (US) launched a new digital health initiative aimed at improving patient engagement and adherence to treatment protocols for male breast cancer patients. This initiative is crucial as it reflects a growing trend towards digitalization in healthcare, enabling better patient outcomes through technology. By integrating digital tools into its treatment regimen, Pfizer (US) is likely to enhance its competitive edge in a market that increasingly values patient-centric approaches.

In August 2025, AstraZeneca (GB) expanded its clinical trial program for a promising new drug specifically targeting male breast cancer. This expansion is indicative of the company's commitment to addressing this rare condition and highlights the potential for new treatment options to emerge. By investing in clinical research, AstraZeneca (GB) is positioning itself as a leader in this specialized area, which may yield significant returns in the long term.

As of November 2025, current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are shaping the landscape, fostering innovation and enhancing operational efficiencies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. Companies that can effectively navigate these trends will likely secure a stronger foothold in the male breast-cancer market.

Key Companies in the US Male Breast Cancer Market market include

Industry Developments

In recent months, the US Male Breast Cancer Market has experienced some significant developments, particularly with advancements in treatment and research efforts by major pharmaceutical companies. Merck and Co has released new findings on targeted therapies which have garnered attention within the medical community. Genentech has been focusing on immunotherapy options for male breast cancer patients, showing promising results in recent clinical trials. AstraZeneca and Bristol Myers Squibb are currently involved in partnerships aiming to enhance drug delivery systems, a crucial area for improving patient outcomes.

A notable acquisition was observed in June 2023 when Gilead Sciences announced their purchase of a biotechnology firm specializing in male-specific cancer research, aligning with their strategy to expand on niche oncology segments. Pfizer and Amgen continue to invest in Research and Development sectors to innovate existing therapies. The market has shown a growth in its valuation due to these focused efforts, which aim to address the unique needs of male breast cancer patients.

Major milestones from previous years, including regulatory approvals for new therapeutics in January 2022 and evidence of rising awareness and research funding, have contributed to a more robust landscape in the US Male Breast Cancer Market.

Future Outlook

US Male Breast Cancer Market Future Outlook

The male breast-cancer market is projected to grow at an 8.73% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

Development of targeted therapies for male patients
Expansion of telehealth services for remote consultations
Investment in awareness campaigns to educate healthcare providers

By 2035, the market is expected to achieve substantial growth and enhanced treatment accessibility.

Market Segmentation

US Male Breast Cancer Market Type Outlook

Ductal Carcinoma in Situ
Paget’s Disease of the Nipple
Inflammatory Breast Cancer
Infiltrating Ductal Carcinoma

US Male Breast Cancer Market Surgery Outlook

Mastectomy
Breast-Conserving Surgery
Lymph Nodes Biopsy

US Male Breast Cancer Market Diagnosis Outlook

Mammography
Biopsy
Fine Needle Aspiration Biopsy
Core Biopsy
Excisional Biopsy
PET Scan
CT Scan
MRI Scan
Other Tests

US Male Breast Cancer Market Treatment Outlook

Local Treatments
Systemic Treatments

US Male Breast Cancer Market Chemotherapy Outlook

Adjuvant Therapy
Neoadjuvant Therapy

US Male Breast Cancer Market Hormone Therapy Outlook

Using Drugs
Orchiectomy (Castration)

US Male Breast Cancer Market Local Treatments Outlook

Surgery
Radiation Therapy

US Male Breast Cancer Market Targeted Therapy Outlook

For HER2 Positive Breast Cancer
For Hormone Receptor Positive Breast Cancer
For Cancer with BRCA Mutations

US Male Breast Cancer Market Systemic Treatments Outlook

Chemotherapy
Hormone Therapy
Targeted Therapy

Report Scope

MARKET SIZE 2024	380.94(USD Million)
MARKET SIZE 2025	414.19(USD Million)
MARKET SIZE 2035	956.52(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.73% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	["Roche (CH)", "Novartis (CH)", "Pfizer (US)", "AstraZeneca (GB)", "Bristol-Myers Squibb (US)", "Merck & Co. (US)", "Eli Lilly and Company (US)", "Johnson & Johnson (US)"]
Segments Covered	Type, Diagnosis, Treatment, Local Treatments, Surgery, Systemic Treatments, Chemotherapy, Hormone Therapy, Targeted Therapy
Key Market Opportunities	Emerging therapies and increased awareness drive growth in the male breast-cancer market.
Key Market Dynamics	Rising awareness and early detection initiatives are reshaping the male breast-cancer treatment landscape.
Countries Covered	US

FAQs

What is the expected market size of the US Male Breast Cancer Market in 2024?

The US Male Breast Cancer Market is expected to be valued at 350.0 USD Million in 2024.

What will be the market size of the US Male Breast Cancer Market by 2035?

By 2035, the overall market is projected to reach a value of 1020.0 USD Million.

What is the expected CAGR for the US Male Breast Cancer Market from 2025 to 2035?

The expected CAGR for the US Male Breast Cancer Market from 2025 to 2035 is 10.212%.

Which type of male breast cancer holds the largest market share in 2024?

In 2024, Infiltrating Ductal Carcinoma is valued at 140.0 USD Million, making it the largest segment.

What will be the market size for Inflammatory Breast Cancer by 2035?

The market size for Inflammatory Breast Cancer is expected to reach 200.0 USD Million by 2035.

Who are the key players in the US Male Breast Cancer Market?

Major players include Merck and Co, Genentech, AstraZeneca, and Pfizer, among others.

What challenges and opportunities exist in the US Male Breast Cancer Market?

Key challenges include treatment accessibility, while opportunities lie in innovation and increasing awareness.

What is the projected growth rate for Paget Disease in the US Male Breast Cancer Market?

The market for Paget Disease is expected to grow to 90.0 USD Million by 2035.

How has the market for Ductal Carcinoma changed from 2024 to 2035?

The Ductal Carcinoma segment is anticipated to grow from 110.0 USD Million in 2024 to 330.0 USD Million in 2035.

What impact do emerging trends have on the US Male Breast Cancer Market?

Emerging trends, including advancements in targeted therapies, are positively impacting market growth.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓